Who Paid My Doc
James Fry
Neurology with Special Qualifications in Child Neurology Nashville, TN Medical Doctor
NPI 1659482305 CMS profile 347967
1916 Patterson St # 104, Nashville, TN 37203
General payments
$79,899
Research payments
$15,424
Ownership & investment interest
$0
Research they led as principal investigator
$2,428,650
Through program year 2025, James Fry of Nashville, TN is reported in the CMS Open Payments database as having received $79,899 across 972 general payments and $15,424 in research payments paid to them. Separately, studies naming them as principal investigator received $2,428,650 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 95th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,137 | 83 | |
| 2025 | Research | $1,655 | 1 | |
| 2024 | General | $3,118 | 110 | |
| 2023 | General | $3,072 | 135 | |
| 2023 | Research | $13,769 | 8 | |
| 2022 | General | $15,320 | 154 | |
| 2021 | General | $39,782 | 213 | |
| 2020 | General | $2,053 | 130 | |
| 2019 | General | $14,417 | 147 |
Beside peers
- James Fry
- Neurology with Special Qualifications in Child Neurology median
- Middle half of Neurology with Special Qualifications in Child Neurology
- National median
In program year 2025, general payments to James Fry were reported at $2,137. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.
Show as a table
| Year | James Fry | Neurology with Special Qualifications in Child Neurology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $14,417 | $262 | $68–$1,313 | $163 |
| 2020 | $2,053 | $188 | $46–$1,222 | $114 |
| 2021 | $39,782 | $183 | $45–$1,356 | $132 |
| 2022 | $15,320 | $229 | $72–$1,177 | $149 |
| 2023 | $3,072 | $269 | $93–$1,195 | $160 |
| 2024 | $3,118 | $300 | $98–$1,428 | $164 |
| 2025 | $2,137 | $276 | $87–$1,522 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 24 drugsPart D claims
535
Drug cost
$1,332,003
Branded share of claims
34.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Sabril Vigabatrin | Brand | 23 | $871,383 | |
| Afinitor Everolimus | Brand | 11 | $216,236 | |
| Xcopri Cenobamate | Brand | 41 | $79,466 | |
| Epidiolex Cannabidiol (Cbd) | Brand | 13 | $59,549 | |
| Trileptal Oxcarbazepine | Brand | 36 | $50,758 | |
| Sympazan Clobazam | Brand | 11 | $42,019 | |
| Oxcarbazepine | Generic | 47 | $3,895 | |
| Lacosamide | Generic | 19 | $1,636 | |
| Zonisamide | Generic | 35 | $1,613 | |
| Carbatrol Carbamazepine | Brand | 11 | $1,094 |
The 10 drugs with the highest cost, of 24 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 15 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Qelbree |
|
$815 | — | — |
| Epidiolex |
|
$338 | 13 | — |
| INGREZZA |
|
$271 | — | — |
| VALTOCO |
|
$258 | — | — |
| Azstarys |
|
$210 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 15 in the dashboard with a free accountRecords
981 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurology with Special Qualifications in Child Neurology in Tennessee
Jesus Pina Garza
Neurology with Special Qualifications in Child Neurology · Nashville, TN
James Wheless
Neurology with Special Qualifications in Child Neurology · Memphis, TN
Richard Finkel
Neurology with Special Qualifications in Child Neurology · Memphis, TN
Jeffrey Neul
Neurology with Special Qualifications in Child Neurology · Nashville, TN
Thomas Ireland
Neurology with Special Qualifications in Child Neurology · Chattanooga, TN
Willie Anderson
Neurology with Special Qualifications in Child Neurology · Johnson City, TN
Related records
Neurology with Special Qualifications in Child Neurology in Tennessee
Practitioners in the same specialty and state, ranked by reported value.
All Neurology with Special Qualifications in Child Neurology
Everyone recorded under this specialty, nationwide.
Doctors in Tennessee
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.